Your browser doesn't support javascript.
loading
Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response.
Zhang, Le; Wirth, Matthias; Patra, Upayan; Stroh, Jacob; Isaakidis, Konstandina; Rieger, Leonie; Kossatz, Susanne; Milanovic, Maja; Zang, Chuanbing; Demel, Uta; Keiten-Schmitz, Jan; Wagner, Kristina; Steiger, Katja; Rad, Roland; Bassermann, Florian; Müller, Stefan; Keller, Ulrich; Schick, Markus.
Affiliation
  • Zhang L; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Wirth M; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Patra U; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Stroh J; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Isaakidis K; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
  • Rieger L; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany.
  • Kossatz S; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Milanovic M; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Zang C; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Demel U; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Keiten-Schmitz J; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
  • Wagner K; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Steiger K; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany.
  • Rad R; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Bassermann F; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany.
  • Müller S; Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Keller U; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Schick M; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
EMBO Mol Med ; 15(9): e16431, 2023 09 11.
Article in En | MEDLINE | ID: mdl-37485814
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: DNA Damage / Lymphoma, B-Cell Type of study: Prognostic_studies Limits: Humans Language: En Journal: EMBO Mol Med Journal subject: BIOLOGIA MOLECULAR Year: 2023 Type: Article Affiliation country: Germany
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: DNA Damage / Lymphoma, B-Cell Type of study: Prognostic_studies Limits: Humans Language: En Journal: EMBO Mol Med Journal subject: BIOLOGIA MOLECULAR Year: 2023 Type: Article Affiliation country: Germany